EGFR and cancer: In conclusion, this study which involved all available data, including data collected from our cancer centers of China and that pooled from previous studies, and identified the clinical profiles of EGFR-TKI application, suggested that EGFR-TKI was found to be an effective treatment in ASC harboring mutations in EGFR.